

**ILLINOIS
PANDAS/PANS
ADVISORY
COUNCIL**

ILLINOIS PANDAS/PANS ADVISORY COUNCIL



2020 Report

December 20, 2020

Compiled by:

Wendy C Nawara, MSW

Dareen Siri, MD, FAAAAI, FAAAAI

TABLE OF CONTENTS

ILLINOIS PANDAS/PANS ADVISORY COUNCIL	3
UNDERSTANDING PANDAS/PANS.....	4
Clinical Presentation	4
Epidemiology/Demographics.....	5
Etiology and Disease Mechanisms for PANDAS (Post-streptococcal symptoms)	6
STANDARD DIAGNOSTIC AND TREATMENT GUIDELINES	7
Absolute Criteria	7
Major Criteria.....	7
Minor Criteria Group 1.....	7
Minor Criteria Group 2.....	7
Additional Supporting Evidence.....	8
Clinical Management	8
2020 RESEARCH	11
PANDAS/PANS BURDEN IN ILLINOIS.....	15
Considerations during the COVID-19 Pandemic.....	16
Increased Mental Health Issues.....	17
COVID Related PANS.....	17
COVID-19 Vaccine Opportunities.....	17
Further Educational and Health-Related Challenges.....	18
INCREASING CLINICAL AWARENESS.....	19
NETWORK OF EXPERTS	20
OUTREACH	21
RECOMMENDATIONS FOR THE FUTURE.....	21
Enact Standard Practice Guidelines.....	21
Develop Mechanisms to Increase Public Awareness.....	22
Provide Outreach to Educators and Parents	22
Increase Understanding of the Burden on Illinois	23
CITATIONS.....	24

ILLINOIS PANDAS/PANS ADVISORY COUNCIL

MEMBERSHIP

- Dr. Dareen Siri, MD, FAAAAI, FAAAAI, Midwest Allergy Sinus Asthma SC, Chairwoman, Springfield, Ill.
- Allison Nickrent, Legislative Liaison, Illinois Department of Public Health
- Michelle Baldock, Assistant Deputy Director, Illinois Department of Insurance
- Gloria E. Barrera, MSN, RN, PEL-CSN, Illinois State Board of Education
- Illinois State Representative Deanne Mazzochi, Elmhurst, Ill.
- Dr. Pamela Campbell, MD, Division Chief Child Psychiatry, Southern Illinois University, Carbondale, Ill.
- Illinois State Senator Tom Cullerton, Villa Park, Ill.
- Caoimhe Dardis, PhD, PANDAS/PANS Parent, Naperville, Ill.
- Illinois State Representative Jennifer Gong-Gershowitz, Glenview, Ill.
- Ardyth Holbrook, LCSW, Lead Medical Social Work Liaison, Edward-Elmhurst Hospital, Naperville, Ill.
- Natalie Lambadjian-Drummond, MD, Whole Child Pediatrics, Yorkville, Ill.
- Kate Morthland, Health Insurance Policy Advisor, Illinois Department of Insurance
- Wendy Nawara, MSW, PANS PANDAS Advocate and Consultant, Naperville, Ill.

The Illinois PANDAS/PANS Advisory Council was created in 2015 in accordance with *Public Act 99-0320* to:

- Make recommendations concerning standard practice guidelines for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections/Pediatric Acute-onset Neuropsychiatric Syndrome (PANDAS/PANS).
- Develop mechanisms to increase clinical awareness of PANDAS/PANS.
- Provide outreach to educators and parents.
- Develop of a network of volunteer experts on PANDAS/PANS to serve as resources within the state.

The Illinois Department of Public Health (IDPH) has managed oversight and support of the council since 2015. The priorities of the council in 2019 have been to continue to review the standards of care that medical providers in the state can access, and to educate citizens, health providers, mental health providers, medical students, and education professionals on PANDAS/PANS.

The council consists of:

- Physicians, who are board certified in immunology, pediatrics, psychiatry, and family medicine and have expertise and experience in the diagnostics and treatments of pediatric autoimmune neuropsychiatric disorders and/or autism spectrum disorders.
- Health and mental health care professionals with expertise and experience in the diagnostics and treatments of pediatric autoimmune neuropsychiatric disorders.
- Certified members of the School Health and Special Education divisions of the State Board of Education.
- Representatives of organizations or groups that advocate on behalf of children and families suffering from PANDAS/PANS and/or Autism Spectrum Disorders
- A principal investigator from the National Institute of Mental Health.
- Legislators.
- Parents of children diagnosed with PANDAS/PANS.

UNDERSTANDING PANDAS/PANS

For 30 years, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) has been studied extensively at the National Institute of Mental Health (NIMH) and elsewhere across the U.S. and internationally.¹ More recently, a consortium of clinicians, researchers, and scientists has dedicated considerable time and effort to clinical care and study of children with PANDAS and the larger cohort of patients with pediatric acute-onset neuropsychiatric syndrome (PANS).² A medically treatable cause can be found for most cases of PANDAS and PANS. Preliminary data suggest that with appropriate treatment early in the course of illness, and effective use of antibiotics prophylaxis, up to 25-30% of childhood mental illnesses may be able to be prevented.³

Evidence has demonstrated that group A Streptococcal infections (GAS) are the causal factor in PANDAS. Antibody studies establish that children with PANDAS have antibodies that invoke bioactivity to produce the acute symptomatology.^{4, 5, 6, 7} Animal studies show the transference of antibodies from an originally infected mouse to a naïve, healthy mouse to produce the same behavioral abnormalities and obsessive-compulsive disorder (OCD) symptoms.^{8, 9} This demonstrates that PANDAS/PANS is an immune mediated antibody process. Placebo-controlled trials of antibiotic therapies demonstrate significant benefits for both PANDAS and PANS, and trials of prophylactic antibiotics have shown that preventing strep infections leads to reduction or cessation of the neuropsychiatric exacerbations.¹⁰ In mild cases with positive strep cultures, a single course of antibiotics given to eradicate the strep infection can be effective in eliminating the psychiatric and behavioral symptoms. Additionally, a growing body of evidence indicates that PANDAS/PANS are autoimmune encephalitic disorders.^{11, 12} There are two different types of autoimmune encephalopathies produced response to infection with group A strep bacteria. One is Sydenham chorea, which is the neurologic manifestation of acute rheumatic fever, while the other is PANDAS.¹³ Because intravenous immunoglobulin (IVIG) is widely accepted as a standard treatment for post-infectious autoimmune encephalopathy,¹² when faced with the more moderate to severe presentations of PANDAS/PANS, physicians must rely on immunomodulatory measures, including steroids, intravenous immunoglobulin, and therapeutic plasmapheresis (TPA) to halt this neuroinflammatory process.

Children with PANDAS/PANS who do not receive appropriate treatment remain chronically ill and the progression of the disease may exacerbate symptomatology to the extent that they are unable to attend school, participate in the community, and, in some cases, may require residential care. In the most severe cases, lack of appropriate medical interventions can result in the progression of clinically associated symptoms, which may result in death due to suicide or complications due to anorexia.

Clinical Presentation

PANDAS and PANS are defined by an unusually abrupt onset of OCD or eating restrictions/anorexia.^{2, 15}

Comorbidity is present in all children, with most having symptoms in at least four categories.^{2, 15, 16}

- Anxiety (particularly separation anxiety)

PANDAS

Pediatric
Autoimmune
Neuropsychiatric
Disorders
Associated with
Streptococcal infections¹

PANS

Pediatric
Acute-onset
Neuropsychiatric
Syndrome²

- Emotional lability and/or depression
- Irritability, aggression, and/or severely oppositional behaviors
- Behavioral (developmental) regression
- Deterioration of school performance
- Sensory or motor abnormalities
- Somatic signs and symptoms, including sleep disturbances, enuresis, and urinary frequency

The course of illness is relapsing/remitting, with exacerbations preceded by infections (particularly group A strep) and psychosocial stressors.


Although early recognition and treatment can eradicate symptoms, children who fail to receive appropriate diagnosis and treatment have increasingly severe episodes, with resultant distress and loss of function (unable to participate in extracurricular activities, stop seeing friends, unable to attend school or even leave a “safe” room in their house). Severe cases often require prolonged psychiatric hospitalizations and may end in death (by suicide, starvation/dehydration, or accidents caused by impulsive behaviors).

Epidemiology/Demographics

- Peak age at onset = 6.5 years²
- Boys outnumber girls approximately 2:1²
- 1 in 250 children have impairing symptoms (estimates from clinic populations^{2,14})
- 5 – 10% of grade school-aged children have observable GAS-related neurologic and behavioral symptoms¹⁴

Etiology and Disease Mechanisms for PANDAS (Post-streptococcal symptoms)

It is understood that 65-100% of patients with Sydenham chorea have OCD symptoms, with that rate increasing with recurrences.¹⁷ OCD symptoms are often more persistent and difficult to treat than the chorea.¹⁸



GAS are “molecular mimics” that cause the immune system to produce antibodies that misrecognize host antigens as foreign. This temporary loss of tolerance may become permanent if blood-brain barrier is breached (which GAS exotoxins can do) or if the immune system is repeatedly activated.¹³

Evidence for an etiologic role of GAS (group A strep) infections in PANDAS comes from:

- Clinical observations showing 1:1 correlation between (occult) GAS infections and neuropsychiatric symptom exacerbations.^{15, 16}
- Epidemiologic studies demonstrating association between GAS infections and choreiform movements, tics, and problem behaviors.^{14, 19}
- Treatment of GAS infections improves OCD/tic symptoms.^{10, 20}
- Prevention of GAS infections reduces number and severity of neuropsychiatric symptom exacerbations.^{21, 22}
- Cross-reactive antibodies present during acute illness, but not during convalescence.^{23, 24}
- Animal models show that repeated GAS infections in lymphoid tissues, such as tonsils and adenoids, stimulate T-cell production and immune activation in the central nervous system.⁹

Evidence for immune dysfunction in PANDAS comes from:

- Efficacy of immunomodulatory therapies, such as IVIG and plasmapheresis.^{25, 26, 27}
- Cross-reactive antibodies produce cell signaling, as evidenced by activation of CaM KII.^{24, 28}
- Animal models have demonstrated that PANDAS sera/antibodies produce neuropsychiatric symptoms, even by passive transfer.^{9, 28, 29, 30}

STANDARD DIAGNOSTIC AND TREATMENT GUIDELINES

The development of the PANDAS/PANS standard diagnostic and treatment guidelines began in 2013 when a group of noted physicians met at the National Institutes of Health to discuss the significant needs of this population of sick children. A diagnostic consensus was developed and subsequently published in the *Journal of Child and Adolescent Psychopharmacology* in 2015.³¹ Follow-up treatment guidelines were published in the same journal in July of 2017.³²

The PANDAS/PANS diagnosis is based on subjective criteria and is considered a clinical diagnosis. However, as research has improved, absolute, major, and minor criteria have been developed and can be met in various combinations.³³

- Sudden Onset. Sudden and precipitous development of symptoms over the course of hours or even a few days.
- Characteristic dynamic evolution of nature of symptoms and intensity of symptoms over a period of 2-6 weeks.

Major Criteria

- Presence of OCD symptoms
- Separation anxiety (one or both)
 1. Daytime and nighttime dependency on parent’s physical presence
 2. Psychological dependence on familiar physical environment with or without need for parents’ presence
- Anorexia (one or more)
 1. Acute onset of food and/or liquid refusal
 2. Fear of choking
 3. Fear of vomiting
 4. Inability to swallow because of intolerable smell or texture
 5. Distorted body image (usually in children over 12; and can result from the other types of anorexia).

Minor Criteria Group 1

- | | |
|--|---|
| <ul style="list-style-type: none"> <input type="checkbox"/> Sleeping disorders (insomnia, night terrors, refusal to sleep alone) <input type="checkbox"/> Behavior regression (baby talk, temper tantrums, behaviors unbecoming of actual chronological age) <input type="checkbox"/> Emotional lability/depression | <ul style="list-style-type: none"> <input type="checkbox"/> Hyperactivity, inattentiveness, inability to concentrate (ADHD/ADD diagnosis compatible) <input type="checkbox"/> Learning disability (particularly mathematics) that was not there prior to symptom onset <input type="checkbox"/> Hallucinations |
|--|---|

Minor Criteria Group 2


- | | |
|--|---|
| <ul style="list-style-type: none"> <input type="checkbox"/> “Hyperalert” appearance and/or “puppet-like” facial mannerisms <input type="checkbox"/> Hypotonia <input type="checkbox"/> Mydriasis (especially during acute phase of symptoms) <input type="checkbox"/> Urinary frequency and/or enuresis and/or daytime incontinence <input type="checkbox"/> Short-term memory loss | <ul style="list-style-type: none"> <input type="checkbox"/> Increased sensory responses (smells, sounds, light, touch) <input type="checkbox"/> Fine motor skills deterioration <input type="checkbox"/> Dysgraphia <input type="checkbox"/> Tics and/or adventitious movements |
|--|---|

Additional Supporting Evidence

- Positive GAS titers
- Positive EBV IgM (VCA) (EBNA)
- Positive ANA titer (speckled)
- Elevated IgE levels
- Leukopenia
- Increased circulating immune complexes (c1q, c3d, Raji cells)
- Sleep study abnormalities
- MRI abnormalities
- EEG abnormalities
- PET scan abnormalities
- Positive response to antibiotic trial
- Positive response to steroid “burst”
- Other positive specific autoimmune encephalopathic antibodies, such as HSV, VZV, EV, HHV-6, AntiNMDAR, ALE, GAD-65
- Cunningham Panel (Moleculera Labs)
- “The best test is still taking a thorough history and listening to the parents.”
— Dr. Sue Swedo, Scientist Emeritus, former chief Neuroscience Branch, NIMH³⁴

Clinical Management


In 2014, more than 40 physicians and researchers representing the fields of immunology, infectious disease, microbiology, neuroimmunology, neurology, pediatrics, psychiatry, and rheumatology from 23 academic institutions across the U.S., Canada, and Australia convened to craft standard of care “best practice” guidelines. These evidence-based, peer-reviewed guidelines, published in the Journal of Child and Adolescent Psychopharmacology in July/Aug 2017,³² show there are three recommended complementary treatment modalities when treating cases of PANDAS/PANS:



1. Removing the **SOURCE** of the inflammation with antimicrobial interventions.
2. Treating disturbances of the immune **SYSTEM** with immunomodulatory and/or anti-inflammatory therapies.
3. Treating the **SYMPTOMS** with psychoactive medications, psychotherapies (particularly cognitive behavioral therapy), and supportive interventions.³²


Early recognition and prompt treatment of occult GAS infections can produce complete symptom remission.²⁰ Antibiotics may help PANS patients, even in the absence of documented GAS infection.⁵ Immunomodulatory therapies, such as steroids, intravenous immunoglobulin (IVIG), or therapeutic plasmapheresis, are helpful for severe, debilitating symptoms.^{25, 26, 27}

Effects of therapeutic plasmapheresis and intravenous immunoglobulin (IVIG) in PANDAS



A. IVIG vs. Placebo vs. Plasmapheresis Improvements: 45%, 0% and 58% respectively.

IVIG and plasmapheresis produced a significant improvement in OCD severity in children with PANDAS, relative to sham IVIG infusion (from Perlmutter et al., 1999).



B. 20% reduction in caudate size following immunomodulatory treatment.

Caudate size was reduced by 20% in a child with PANDAS after immunomodulatory treatment (from Giedd et al., 1996).

Additionally, the PANDAS Physicians Network has developed a diagnostic flowchart for physicians to aid in recognition and treatment (<https://www.pandasppn.org/flowchart>). This chart is updated frequently to reflect most up to date knowledge on the condition. Physicians and mental health providers are encouraged to check the site regularly.³⁵

Quite often, children with PANDAS/PANS are also identified as having co-occurring conditions, including, but not limited to, autism spectrum disorders, immune deficiencies, or other autoimmune illnesses or encephalopathies. In these cases, as in all cases of potential neuroimmune illness, it is important that treatment decisions are made to ensure the best possible clinical outcome. For example, if a child has both a moderate to severe PANDAS and a documented immune deficiency warranting immunomodulatory treatment, a “loading dose” of immunoglobulin may be required to halt the autoimmune attack before proceeding with the more typical monthly doses prescribed for the immune deficiency.

It is the recommendation of this advisory council that the diagnostic criteria, practice parameters, and treatment protocols identified here shall continue to be practiced as the standard of care for PANDAS/PANS in Illinois. **However, it is imperative that more physicians, educators, and mental health providers become aware of the condition and how to treat it.**

2020 RESEARCH

[Preclinical Animal Models Advance Knowledge of Post-Infectious BGE Neuropsychiatric consequences of childhood group A streptococcal infection: A systematic review of preclinical models.](#)

Mora S, Martín-González E, Flores P, Moreno M. Brain Behav Immun. 2019 Feb 25. pii: S0889-1591(19)30214-4. DOI: 10.1016/j.bbi.2019.02.027. PMID: 30818033.

[Focus on Cardiologic Findings in 30 Children With PANS/PANDAS: An Italian Single-Center Observational Study.](#)

Murciano M, Biancone DM, Capata G, Tristano I, Martucci V, Guido CA, Anaclerio S, Loffredo L, Zicari AM, Duse M, Spalice A.

Front Pediatr. 2019 Oct 1;7:395. doi: 10.3389/fped.2019.00395. eCollection 2019. PMID: 31632938 Free PMC article.

[Microglial Phagocytosis of Neurons: Diminishing Neuronal Loss in Traumatic, Infectious, Inflammatory, and Autoimmune CNS Disorders.](#)

Yanuck S. Front Psychiatry. 2019; 10: 712. Published online 2019 Oct 3. doi: 10.3389/fpsyt.2019.00712. PMID: 31632307.

[From the Editor-in-Chief's Desk.](#)

Koplewicz HS. J Child Adolesc Psychopharmacol. 2019 Oct;29(8):575. doi:

10.1089/cap.2019.29173.hsk. PMID: 31592723 No abstract available.

[Infections, Antibiotics, and Mental Health Deteriorations.](#)

Chan A, Frankovich J. J Child Adolesc Psychopharmacol. 2019 Oct;29(8):647-648. doi:

10.1089/cap.2019.0100. Epub 2019 Jul 29. PMID: 31355667 No abstract available.

[Wilson Disease in a Child With Mild Neuropsychiatric and Hepatic Involvement: A Challenging Diagnosis for a Heterogeneous Disorder.](#)

Mosca A, Nicita F, Capuano A, Nobili V. J Pediatr Gastroenterol Nutr. 2019 Oct;69(4):e118-e119.

Doi: 10.1097/MPG.0000000000002433. PMID: 31246682 No abstract available.

[Establishing a Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic: Baseline Clinical Features of the Pediatric Acute-Onset Neuropsychiatric Syndrome Cohort at Karolinska Institutet.](#)

Gromark C, Harris RA, Wickström R, Horne A, Silverberg-Mörse M, Serlachius E, Mataix-Cols D. J

Child Adolesc Psychopharmacol. 2019 Oct;29(8):625-633. doi: 10.1089/cap.2018.0127. Epub

2019 Jun 5. PMID: 31170007 Free PMC article.

[Clinical-Serological Characterization and Treatment Outcome of a Large Cohort of Italian Children with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection and Pediatric Acute Neuropsychiatric Syndrome.](#)

Lepri G, Rigante D, Bellando Randone S, Meini A, Ferrari A, Tarantino G, Cunningham MW,

Falcini F. J Child Adolesc Psychopharmacol. 2019 Oct;29(8):608-614. doi:

10.1089/cap.2018.0151. Epub 2019 May 29. PMID: 31140830

[Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection \(PANDAS\) and pediatric acute-onset neuropsychiatric syndrome \(PANS\): Changes in antineuronal antibody titers parallel changes in patient symptoms.](#)

Shimasaki C, Frye RE, Trifiletti R, Cooperstock M, Kaplan G, Melamed I, Greenberg R, Katz A, Fier E, Kem D, Traver D, Dempsey T, Latimer ME, Cross A, Dunn JP, Bentley R, Alvarez K, Reim S,

Appleman J. J Neuroimmunol. 2020 Feb 15;339:577138. doi: 10.1016/j.jneuroim.2019.577138. Epub 2019 Dec 15. PMID: 31884258

[Assessment and management of tic disorders and Tourette syndrome by Australian paediatricians.](#)

Efron D, Payne J, Gulenc A, Chan E. J Paediatr Child Health. 2020 Jan;56(1):136-141. doi: 10.1111/jpc.14541. Epub 2019 Jun 17. PMID: 31206903

[Azithromycin Prophylaxis in an Adolescent With PANDAS.](#)

Blankenship P, Kurek K. J Pediatr Pharmacol Ther. 2020 Jan-Feb;25(1):61-63. doi: 10.5863/1551-6776-25.1.61. PMID: 31897077 Free PMC article.

[Pediatric Acute-Onset Neuropsychiatric Syndrome and Catatonia: A Case Report.](#)

Schlansky K, Facer B, Tanguturi YC, Cundiff AW, Fuchs DC. Psychosomatics. 2020 Jan-Feb;61(1):86-91. doi: 10.1016/j.psym.2019.03.007. Epub 2019 Apr 3. PMID: 31079934 No abstract available.

[Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection \(PANDAS\) and pediatric acute-onset neuropsychiatric syndrome \(PANS\): Changes in antineuronal antibody titers parallel changes in patient symptoms.](#)

Shimasaki C, Frye RE, Trifiletti R, Cooperstock M, Kaplan G, Melamed I, Greenberg R, Katz A, Fier E, Kem D, Traver D, Dempsey T, Latimer ME, Cross A, Dunn JP, Bentley R, Alvarez K, Reim S, Appleman J. J Neuroimmunol. 2020 Feb 15;339:577138. doi: 10.1016/j.jneuroim.2019.577138. Epub 2019 Dec 15. PMID: 31884258

[Alterations in the Nervous System and Gut Microbiota after \$\beta\$ -Hemolytic Streptococcus Group A Infection-Characteristics and Diagnostic Criteria of PANDAS Recognition.](#)

Baj J, Sitarz E, Forma A, Wróblewska K, Karakuła-Juchnowicz H. Int J Mol Sci. 2020 Feb 21;21(4):1476. doi: 10.3390/ijms21041476. PMID: 32098238 Free PMC article. Review.

[Obsessive-compulsive disorder in children and adolescents: epidemiology, diagnosis and management.](#)

Nazeer A, Latif F, Mondal A, Azeem MW, Greydanus DE. Transl Pediatr. 2020 Feb;9(Suppl 1):S76-S93. doi: 10.21037/tp.2019.10.02. PMID: 32206586 Free PMC article. Review.

[N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.](#)

Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. J Child Adolesc Psychopharmacol. 2020 Feb;30(1):32-37. doi: 10.1089/cap.2019.0041. Epub 2019 Dec 3. PMID: 31800306; PMCID: PMC7133418.

[Oxidative stress and gut-derived lipopolysaccharides in children affected by paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.](#)

Loffredo L, Spalice A, Salvatori F, De Castro G, Guido CA, Zicari AM, Ciacci P, Battaglia S, Brindisi G, Ettorre E, Nocella C, Salvatori G, Duse M, Violi F, Carnevale R. BMC Pediatr. 2020 Mar 18;20(1):127. doi: 10.1186/s12887-020-02026-8. PMID: 32188439 Free PMC article.

[Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis.](#)

Platt M, Bolding K. A., Wayne C. R., Chaudhry S, Cutforth T, Franks K. M., Agalliu D. Proceedings of the National Academy of Sciences Mar 2020, 117 (12) 6708-6716; DOI: 10.1073/pnas.1911097117.

[Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient.](#)

Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman M. S., Benseler S. M., Frankovich J, Gorman M. P., Van Haren K, Dalmau J, Dale R. C.. Neurol Neuroimmunol Neuroinflamm Mar 2020, 7 (2) e663; DOI: 10.1212/NXI.0000000000000663

[Benefits of IVIG in Pediatric Acute-Onset Neuropsychiatric Syndrome.](#)

Melamed I, Kobayashi R, O'Connor M, Kobayashi A. L., Schechterman A, Heffron M, Canterberry S, Miranda H, Rashid N. Neurology Apr 2020, 94.

[Antibodies could provide new treatment for OCD.](#)

Queen Mary University of London. ScienceDaily, 21 April 2020.

[Neuropsychiatric consequences of childhood group A streptococcal infection: A systematic review of preclinical models.](#)

Mora S, Martín-González E, Flores P, Moreno M. Brain Behav Immun. 2020 May;86:53-62. doi: 10.1016/j.bbi.2019.02.027. Epub 2019 Feb 25. PMID: 30818033

[Pediatric Acute-Onset Neuropsychiatric Syndrome: A Data Mining Approach to a Very Specific Constellation of Clinical Variables.](#)

Gagliano A, Galati C, Ingrassia M, Ciuffo M, Alquino MA, Tanca MG, Carucci S, Zuddas A, Grossi E. J Child Adolesc Psychopharmacol. 2020 Oct;30(8):495-511. doi: 10.1089/cap.2019.0165. Epub 2020 May 28. PMID: 32460516

[Association of Pediatric Acute-Onset Neuropsychiatric Syndrome With Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic Resonance Imaging.](#)

Zheng J, Frankovich J, McKenna ES, Rowe NC, MacEachern SJ, Ng NN, Tam LT, Moon PK, Gao J, Thienemann M, Forkert ND, Yeom KW. JAMA Netw Open. 2020 May 1;3(5):e204063. doi: 10.1001/jamanetworkopen.2020.4063. PMID: 32364596 Free PMC article.

[Autoantibody Biomarkers for Basal Ganglia Encephalitis in Sydenham Chorea and Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections.](#)

Chain JL, Alvarez K, Mascaro-Blanco A, Reim S, Bentley R, Hommer R, Grant P, Leckman JF, Kawikova I, Williams K, Stoner JA, Swedo SE, Cunningham MW. Front Psychiatry. 2020 Jun 24;11:564. doi: 10.3389/fpsy.2020.00564. eCollection 2020. PMID: 32670106 Free PMC article.

[Familial Clustering of Immune-Mediated Diseases in Children with Abrupt-Onset Obsessive Compulsive Disorder.](#)

Chan A, Phu T, Farhadian B, Willett T, Thienemann M, Frankovich J. J Child Adolesc Psychopharmacol. 2020 Jun;30(5):345-346. doi: 10.1089/cap.2019.0167. Epub 2020 Apr 20. PMID: 32311283 No abstract available.

[Antibodies From Children With PANDAS Bind Specifically to Striatal Cholinergic Interneurons and Alter Their Activity.](#)

Xu J, Liu RJ, Fahey S, Frick L, Leckman J, Vaccarino F, Duman RS, Williams K, Swedo S, Pittenger C. Am J Psychiatry. 2020 Jun 16:appiajp202019070698. doi: 10.1176/appi.ajp.2020.19070698. Online ahead of print. PMID: 32539528

[Abrupt and Severe Obsessive-Compulsive Disorder in an 11-Year-Old Girl-PANDAS/PANS Syndrome: An Entity to be Considered-Management Implications.](#)

Khodayar-Pardo P, Álvarez-Bravos L. J Dev Behav Pediatr. 2020 Jun/Jul;41(5):406-409. doi: 10.1097/DBP.0000000000000807. PMID: 32559053 Retracted.

[Neurological associations of COVID-19](#)

Mark A Ellul, MRCP, Laura Benjamin, PhD, Bhagteshwar Singh, MRCP, Suzannah Lant, MBChB, Benedict Daniel Michael, PhD, Ava Easton, PhD, et al. Published: July 02, 2020; 19(9): 767-783. DOI: [https://doi.org/10.1016/S1474-4422\(20\)30221-0](https://doi.org/10.1016/S1474-4422(20)30221-0).

[CE: PANDAS: Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection.](#)

Pabst C, Subasic K. Am J Nurs. 2020 Aug;120(8):32-37. doi: 10.1097/01.NAJ.0000694332.85367.d0. PMID: 32665509

[PANS may be more prevalent than thought.](#)

Jeff Craven. Clinical Psychiatric News, 2020 Aug 3.

[Hypoferritinemia and iron deficiency in youth with pediatric acute-onset neuropsychiatric syndrome.](#)

Chan A, Karpel H, Spartz E, Willett T, Farhadian B, Jeng M, Thienemann M, Frankovich J. Pediatr Res. 2020 Aug 3. doi: 10.1038/s41390-020-1103-3. Online ahead of print. PMID: 32746449

[Tourette syndrome or PANDAS-a case report.](#)

Singh R, Nekrasova N, Butov D. Wien Med Wochenschr. 2020 Sep 21. doi: 10.1007/s10354-020-00779-6. Online ahead of print. PMID: 32955635

[Pediatric Acute-Onset Neuropsychiatric Syndrome: A Data Mining Approach to a Very Specific Constellation of Clinical Variables.](#)

Gagliano A, Galati C, Ingrassia M, Ciuffo M, Alquino MA, Tanca MG, Carucci S, Zuddas A, Grossi E. J Child Adolesc Psychopharmacol. 2020 Oct;30(8):495-511. doi: 10.1089/cap.2019.0165. Epub 2020 May 28. PMID: 32460516

[Severe Psychotic Symptoms in Youth with PANS/PANDAS: Case-Series.](#)

Pavone P, Parano E, Battaglia C, Marino S, Trifiletti RR, Marino SD, Falsaperla R. J Child Adolesc Psychopharmacol. 2020 Nov;30(9):567-571. doi: 10.1089/cap.2020.0050. Epub 2020 Jul 17. PMID: 32700992

PANDAS/PANS BURDEN IN ILLINOIS

Historically, the true incidence of PANDAS/PANS is unknown. The lack of information on incidence is grounded in the fact that current and prior diagnostic coding for PANDAS and PANS result from the lack of a unique diagnostic code specific to these syndromes. Currently, ICD-10 codifies PANDAS under generalized immune disorders (D89.89 Other specified disorders involving the immune mechanism, not elsewhere classified³⁶). Although ICD-11 more aptly denotes that PANDAS is an autoimmune CNS disorder (8E4A.0 Paraneoplastic or autoimmune disorders of the central nervous system, brain, or spinal cord³⁷), a specific code remains absent. Moreover, the dilemmas in coding PANS are similar and more profound. The lack of adequate coding creates not only disagreement on how to classify these syndromes, but also an inability to track the disorder and compute epidemiological data, and likely results in inadequate reimbursement from insurance claims by health care providers and institutions involved in the care of PANDAS/PANS children. In turn, formulation of diagnostic guidelines and estimation of costs of care become difficult with the paucity of accurate data. It is the opinion of this council that it is imperative for legislators and insurers to work closely with clinical experts to develop clear and consistent coding, to collect accurate statistics on prevalence, and to analyze health care claims data, in order to standardize and to improve care for these pediatric patients in Illinois.

Expert members of the PANDAS/PANS Collaborative Consortium estimate PANDAS/PANS to affect 1-2% of the pediatric population,³⁸ while the non-profit organization PANDAS Network reports the incidence at 1 in 200 children.³⁹ This is not a small number of children who may be affected by PANDAS/PANS. It is clear that a subset of pediatric mental health problems is the result of and embedded within the population of children diagnosed with PANDAS/PANS. In accordance with the Illinois Mental Health 2013-2018 Strategic Plan, children suffering from PANDAS/PANS meet the definition of having a serious emotional disturbance, which is defined as the “unique needs of children and adolescents under age 18 who have, in the past year, been diagnosed with a mental, emotional, or behavioral disorder resulting in functional impairment that substantially interferes with or limits the child’s role or functioning in family, school, or community activities.”⁴⁰ On a national scale, the Centers for Disease Control and Prevention (CDC) reports that 1 in 7 U.S. children between 2 and 8 years of age have a mental, behavioral, or developmental disorder. The National Research Council and Institute of Medicine estimate a higher prevalence of up to 20% of U.S. children (1 out of 5) who experience a mental disorder in a given year.⁴¹ Suicide, which can result from the interaction of mental disorders and other factors, was the second leading cause of death among adolescents aged 12–17 years in 2010.⁴² When mental health issues persist into adulthood, especially as a result of misdiagnosis or inadequate care, the risk of poor school outcomes, decreased employment, additional health concerns, early mortality, and the cost of caring for people with the disorders is heightened.⁴¹ Without a doubt, pediatric mental health problems are a significant predictor for mental health issues in adulthood and are a substantial public health concern.

A 2016 collaborative study from the PANDAS Network, the University of Buffalo, and the University of South Florida revealed that prompt diagnosis and expeditious treatment of this condition can alleviate symptoms in the short term but can also alter the course of the disease in the long term.⁴³ While it is appreciated by a small percentage of clinicians that timely antibiotic intervention and eradication of the inciting infection are integral in the treatment of PANS, this study, for the first time, highlights the importance of such treatment in the long-term clinical picture of PANS. Although PANS is typically recurrent with some chronic features, the data reported herein suggest that early and aggressive treatment of infection may decrease both the likelihood of residual symptoms and the likelihood of recurrence, potentially preventing the high levels of functional impairment seen particularly in the post-pubertal years. Having increased vigilance for new infections and exposure to GAS is likely also helpful to

minimize the impact of recurrence of PANS symptoms.⁴³ Without appropriate diagnosis and treatment, the illness has the potential to become a chronic life-long condition, requiring extensive and expensive care. There can be no doubt that mental, behavioral, and developmental disorders, such as PANDAS/PANS, and the associated conditions of attention deficit hyperactivity disorder, OCD, autism spectrum disorders, and Tourette syndrome have a substantial impact on the health care, families, and communities of Illinois.

In the 2019 census of approximately 2.8 million children under age 18 living in Illinois, the 0.5% low estimation of PANDAS/PANS amounts to approximately 14,000 affected children statewide. Of approximately 150,000 children diagnosed with mental illness in Illinois, due to the under recognition of PANDAS/PANS, a larger subset of these children may actually have pediatric acute onset neuropsychiatric syndrome. Given the treatable medical nature and potential full reversal of neurocognitive deficits in PANDAS affected children, if appropriately diagnosed and treated immediately, the number of children with mental health conditions overall could be reduced, which would substantially limit the burden on the state. As already mentioned, NIMH has estimated 25-30% of childhood mental illness may be preventable through appropriate treatment of PANDAS/PANS.³ By computing this estimation with the data suggested by the Illinois Mental Health Strategic Plan,⁴⁰ in 2013 approximately 43,750-52,500 children and adolescents may have decreased quality of life due to a missed diagnosis of PANDAS/PANS and/or misdiagnosis of serious emotional disturbance.

The financial cost of caring for children with serious mental illnesses (SMI) is profound, and even more so in children with PANDAS/PANS who require concomitant medical, psychiatric, and behavioral treatments. It is estimated the **excess** lifetime cost burden of SMI is \$1.85 million per person⁴⁴ and that inpatient and outpatient costs amount to \$247 billion spent on childhood mental disorders in the U.S. annually.⁴³ Hospitalizations due to PANDAS/PANS are significantly more expensive for the Illinois health care system than community-based services. The average length of stay for a child in Illinois with a psychotic disorder, not otherwise specified (NOS), is 17.9 days.⁴⁵ A recent estimate reveals that a five-day psychiatric hospitalization can cost \$12,000 in Greater Chicago.⁴⁶ Currently, the council experts recognize that the majority of Illinois children with PANDAS/PANS experience significant delays, usually several years or more, before receiving adequate diagnosis and treatment. In comparison, the costs of early diagnosis and treatment with generic antibiotics and anti-inflammatories are a significant fraction. The vast economic benefits, in addition to improved medical and social welfare of the affected child and their families, direct the council to stress the urgency for recognition and treatment of PANDAS/PANS at the initial abrupt onset of symptoms.

Considerations during the COVID-19 Pandemic

The 2019 coronavirus pandemic (COVID-19) has resulted in profound changes in society, from increased attention to infectious disease transmission and medical evolution of a novel infectious agent, to the engagement of public health measures in response to a dire population crisis, and to the personal and collective mental health challenges brought about by normative and often mandated shifts in behavior. There can be no denying that this pandemic has created a watershed moment with long-lasting effects on the population. There are a number of social and medical implications of COVID-19 on the PANDAS/PANS cohort that exist, which may similarly affect other groups of children and adults suffering from chronic illness. The council believes the public's heightened interest and understanding of the above factors will result in increased empathy for those suffering with PANDAS/PANS and a renewed drive for education and research in post- and para-infectious neurocognitive disorders.

Increased Mental Health Issues

Prior to the COVID-19 pandemic, the council was aware that mental health issues amongst children were increasing. The burden of pediatric mental health disorders is significant, with upwards of 10% of all pediatric hospitalizations attributed to mental health conditions.⁴⁷ An estimated 20% of children and adolescents in the United States meet diagnostic criteria for a mental health disorder.⁴⁷ The CDC reports that attention deficit hyperactivity disorder (ADHD), behavior problems, and depression were the most commonly diagnosed mental disorders in children.⁴⁸

- 9.4% of children aged 2-17 have received an ADHD diagnosis.⁴⁸
- 7.4% of children aged 3-17 have a diagnosed behavior problem.⁴⁸
- 7.1% of children aged 3-17 have a diagnosed anxiety disorder.⁴⁸
- 2-3% of children and adolescents have OCD.⁴⁹
- While less prevalent, but nonetheless concerning, collected tic disorder statistics on children are estimated to fall in a .4-.8% range.⁵⁰

Globally, the incidence of mental health issues in children have risen since the start of the COVID-19 pandemic.^{51, 52, 53} Anxiety, depression, difficulty concentrating, boredom, restlessness, loneliness, irritability, and worrying, are just some of the symptoms being reported. Although the rise of mental health disorders in children may be attributed to a number of factors, including quarantining, school interruption, parental anxiety, uncertainty for the future, and economic instability. A proportion of these presenting disorders may be due to post-infectious complications of a medical disease. A 2018 study reported a significant percentage of pediatric OCD patients meet the requirements for a PANDAS/PANS diagnosis, highlighting the need for screening upon the appearance of initial symptoms.⁴⁷ It must be underscored that a variety of mental health disorders are a part of the presenting symptomatology in a PANDAS/PANS diagnosis and should be investigated.

COVID-Related PANS

In less than a year, a multitude of unexpected and serious medical complications and sequelae of COVID-19 have emerged, including a variety of neurological and neuroinflammatory disorders. The multisystem inflammatory syndrome in children (MIS-C), a complication of pediatric COVID-19 infection, has emerged, lending a host of neurological complications thought to arise from central nervous system (CNS) insult, whether from metabolic or hypoxic injury. In addition, the SARS-CoV-2 virus itself, a cytokine storm induced by viral infection, or post-inflammatory antibody response, may cause other CNS and neuropsychiatric problems. COVID-19-induced headache, dizziness, delirium, cognitive difficulties, change in mental status, acute cerebrovascular events, mood disorders, acute necrotizing encephalopathy, meningoencephalitis, and autoimmune encephalopathy have been reported.^{50, 54} These issues call for increased vigilance in screening and monitoring children for PANDAS/PANS and similar disorders, during and after a COVID-19 infection.

COVID-19 Vaccine Opportunities

COVID-19 vaccines are needed to reduce morbidity and mortality in high-risk groups, like older adults, and will be allocated to such groups first. An estimated 25-50% of the population would need to be immune in order to suppress current rates of community transmission.⁵⁵ Given the current availability of COVID-19 vaccines and allocation plans, younger children will not be immunized for some time and will be at-risk for natural infection until population targets are achieved. Pediatric trials are in initial stages and, eventually, a COVID-19 vaccination may be approved for pediatric use.

Although young children infected with COVID-19 appear to have a milder course and a better prognosis than adults,⁵⁶ a minority of children have experienced severe courses and have had devastating tolls. Such cases are rare with underlying risk factors for severity that include very young age and co-morbidities, such as immunological conditions (immunodeficiency and immunosuppression), respiratory conditions (asthma, cystic fibrosis), and neurological disability.⁵⁷ Similar to other viral pathogens and their vaccines, a natural COVID-19 infection and its ensuing symptomatology may be reduced and potentially prevented by the COVID-19 vaccination. Prevention of natural infection and its complications may be speculated to reduce COVID-19-related PANS as well.

PANDAS/PANS children are known to have immune-dysregulation and a significant proportion have an immunodeficiency status,⁵⁸ causing them to be potentially more susceptible to, and vulnerable to complications of infection. Given this knowledge, the cohort of PANDAS/PANS children who have co-existing immunodeficiency might be considered for prioritization among the pediatric population to receive a COVID-19 vaccine. The complexities of the immune system and its function in each specific child must be considered. For most people who have immunodeficiency, the humoral response to viruses is preserved and most children would still benefit from COVID-19 vaccination. However, for some children with specific immunodeficiencies or who are undergoing immunosuppressive or immunomodulatory treatment, a vaccination may not make sense since the body is unable to mount any effective response to the vaccine or the vaccine might be neutralized by immunomodulatory treatment. In such cases, the vaccine would in essence be wasted on the individual. In certain circumstances of combined immunodeficiencies, live vaccines may result in adverse outcomes.⁵⁹ The COVID-19 vaccines available at the time of this report do not include an approved or upcoming live or live-attenuated vaccine. Reports of allergic reactions in certain susceptible individuals have also rarely occurred in early stages of public vaccination efforts, likely to the polyethylene glycol component of the first COVID-19 vaccines available in Western countries.⁶⁰ The decision to immunize to COVID-19 the PANDAS/PANS child who has a concomitant immunodeficiency, who is on an immunosuppressive or immunomodulatory treatment, and/or who has allergic predispositions, is best individualized. It is important for parents and caregivers of children with immune problems to defer immunization and first consult with their immunologist. For children with comorbid severe allergies, such as asthma, eczema, or food and drug allergy, a discussion with the treating allergist may be strongly advised.

Further Educational and Health-Related Challenges

Like all children who suffer from chronic diseases, children with PANDAS/PANS and their families are socially and economically vulnerable. They are already at an increased risk for social isolation and have significant educational challenges. Quarantining measures resulting in school closures may further limit the ability of families, particularly families with limited financial resources, to initiate and to maintain mental health counseling, therapeutic and assistive services, and special educational supports, most of which are school based. The pandemic has also resulted in barriers to adequate health care, including delays in preventative and health maintenance services, appointment scheduling, and diagnostic testing. These barriers are compounded by even more stringent self-imposed isolation measures that families have initiated to protect themselves from increased risks of contracting COVID-19 in order to prevent exacerbating PANDAS/PANS symptoms. Manifestations of these fears and anxieties have been observed to include school refusal, increased separation anxiety, and sleep issues.

As discussed above, PANDAS/PANS children are known to have immune-dysregulation and immunodeficiency,⁵⁸ with resultant increased susceptibility to infection and/or their complications. On the other hand, behavioral issues, sensory issues, and anxiety might make common strategies for

prevention, such as mask-wearing, usual hygiene practices, and some social distancing methods difficult to perform. Many families might choose to avoid or to delay the evaluation of a respiratory illness in their child(ren), either due to fear of catching COVID-19 when attempting to secure medical care, due to insufficient funds, or due to the fear of stigma and consequences of testing positive for COVID-19. These reasons might cause the incidence of PANDAS/PANS to rise, since GAS infections may be missed more often result of less in-person health care being delivered, since GAS may not be sufficiently evaluated under the weight of COVID-19 screening and testing fervor, or since GAS may be empirically treated for general respiratory infection with less effective antimicrobials without sufficient testing. Delays in the rapid evaluation and treatment of GAS with adequate antimicrobials, as well as the use of too-short or ineffective antibiotics, have resulted in the increased risk of GAS-related rheumatic heart disease,⁶¹ and perhaps other immune-mediated GAS complications such as Sydenham’s chorea and PANDAS. While there are currently no clear-cut solutions to some of the dilemmas, having an understanding of treatment barriers will facilitate better decision-making among physicians, educators, mental health providers, legislators, insurers, and other stakeholders.

INCREASING CLINICAL AWARENESS

- The Illinois Department of Public Health (IDPH) has created a PANDAS/PANS tab on its website to enable users to learn more about PANDAS/PANS. The tab also provides direct links to the PANDAS Physicians Network flowchart to aid in ease of recognizing the disorder and includes resources for physicians and families. The tab is currently under Child and Maternal Health; however, it is difficult for health care providers to find. The council recommends the tab be listed under Diseases.
- Due to the COVID-19 pandemic, the last in-person PANDAS/PANS Summit occurred December 3, 2019. The summit goals were to encourage necessary collaboration between the advisory council/IDPH, mental health and education professionals, physicians, and the community. Three presentations were given to the community of physicians, mental health providers, educational providers, and children’s health advocates. The presentations can be viewed at:
 - PANS/PANDAS and Immunodeficiency - Dareen Siri, MD, FAAAAI, FACAAI
<https://youtu.be/kDbW434MBK4>
 - Introduction to Navigating Insurance for PANS/PANDAS - Michelle Baldock, assistant deputy director, Illinois Department of Insurance
<https://youtu.be/Gix0M2A271k>
 - PANS/PANDAS in the School Environment - Teresa Schindler, RN, PEL-CSN
https://youtu.be/zPi6m_DJWK0
- A 2021 virtual summit and grand round is planned for April 23, 2021. The Southern Illinois University Psychiatry Department is hosting this event and providing CMEs (continuing medical education) for health care providers. Plans for subsequent meetings are underway to include topics on educational considerations, insurance and legislation, and parental support.
- The development of presentations that would yield the participants credit for professional education has been investigated. These presentations would be available to members of the council to give upon request. A presentation for schools and teachers has been developed and presented in Naperville, Aurora, and Mokena school districts.

- In collaboration with the Illinois Department of Insurance, a document to answer frequently asked questions pertaining to Charlie’s Law and the Autoimmune Encephalitis Coding Law has been developed and is available on the Illinois Department of Insurance website. A better understanding of navigating the insurance process is needed by families and physicians. For that reason, the council recommends the document be available to the public through both the Illinois Department of Insurance and the IDPH’s website page on PANDAS/PANS.
- Encouraged appropriate and consistent access to care for families in need of treatment. Suggested the use of state and national experts when conducting peer-to-peer reviews as other specialists may not yet have sufficient knowledge or experience to offer an informed opinion on physician recommended care.
- Members of the PANDAS/PANS Advisory Council exhibited at both the Illinois Chapter of the American Academy of Pediatrics and the National American Academy of Pediatrics (AAP) conferences in early 2020.
- The World Health Organization announced on June 18, 2018 its preparations for the ICD-11 (International Classifications of Diseases) to be implemented in 2021. Having a code for PANDAS would allow better access to insurance covered care for all families in Illinois as it describes PANDAS as an autoimmune encephalopathy. The diagnostic code is 8E4A.0
- The council supports Charlie’s Law, P.A. 100-0024, that was signed and effective on July 18, 2017. This law should have enabled children in Illinois to access insurance covered care for treatments of PANDAS/PANS. Because families continue to be met with roadblocks from insurers regarding this law, members of the council supported efforts of legislators to introduce a subsequent clarifying bill that would make it easier for families and physicians to gain access to treatments covered by insurance. Legislation for introduction in 2021 is currently under consideration.
- The council supports the Autoimmune Encephalitis Coding Public Act, PA 101-0448, that was signed into law on August 23, 2019. For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall be coded as autoimmune encephalitis until the American Medical Association and the Centers for Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. The act provides that thereafter, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.
- Council advocacy for future legislation as it pertains to meeting the needs of PANDAS/PANS families will be ongoing.

NETWORK OF EXPERTS

Throughout the country there are many physicians practicing in the relevant clinical areas pertaining to the diagnostics and treatment of PANDAS/PANS. In addition, there are scientists continually researching the condition to improve upon the care of children. The PANDAS/PANS Collaborative Consortium members are listed here:

- **Harvard (MGH)** – Kyle Williams and Dan Geller (Child Psych), Mark Pasternack (Peds ID)
- **Yale** – James Leckman, Robert King (both Child Psych)

- **Columbia** – Dritan Agalliu (Basic Science of blood-brain barrier), Tyler Cutforth (Basic Science), Wendy Vargas (Neurology), and Shannon Delaney (Child Psychiatry, Lyme)
- **Nemours/Delaware Children’s Hospital** – Jo Elia (Child Psych), Harry Chugani (PET neuroimaging)
- **NIMH** – Susan Swedo (Scientist Emerita, Pediatrics)
- **Georgetown** – Beth Latimer (Pediatric Neuro), Earl Harley (ENT) and Heidi Appel (Pediatrics)
- **University of South Florida** – Tanya Murphy (Child Psych), Jolan Walter (Immunology)
- **Loyola University** (Hinsdale, Ill.) – Miro Kovacevic (Pediatrics)
- **University of Minnesota** – Pat Cleary (basic science, microbiology of Group A strep), Gail Bernstein (Psychiatry)
- **Baylor University** – Eyal Muscal (Peds Rheumatology)
- **The University of Oklahoma** – Madeleine Cunningham (GAS microbiology; immune response to infection)
- **University of Arizona** – Sydney Rice (Dev/Behav Peds), Michael Daines (Peds Immunology), Chris Speakerman (Nurse Practitioner)
- **Stanford University** – Jenny Frankovich (Peds Rheumatology), Margo Thienemann (Child Psych)
- **Moleculera Labs** - Craig Shimasaki (Antibody Testing)
- **PANDAS Physicians Network** – David Brick (Pediatric Cardiology)
- **University of California San Diego** - Jay Giedd (Pediatrics)
- **Virginia Commonwealth University/ Medical College of Virginia (MCV)** - Wei Zhao (Immunology) and David Jaffe (Neurology)
- **Miami Children’s Hospital** - Reuven Bromberg (Rheumatology) and Ann Hyslop (Neurology)

Within Illinois, the practicing past and present members of this advisory council can be consulted for their expertise in the appropriate areas.

- Gloria Barrera, MSN, RN, PEL-CSN, RN, course facilitator, Illinois State Board of Education
- Teresa Schindler, RN, PEL-CSN
- Pamela Campbell, MD, Child Psychiatry, Southern Illinois University
- Anette Mnabhi, DO, Synergy Healthcare
- Wendy Nawara, MSW, board president, ASPIRE
- Greg Sharon, MD, Immunologist, Asthma, and Allergy Center
- Anjum Usman-Singh, MD, True Health Medical Center
- Dareen Siri, MD, FAAAAI, FAAAAI, Midwest Allergy Sinus Asthma, SC
- Ardyth Holbrook, LCSW, Edward-Elmhurst Hospital

OUTREACH

- The professional members of the council are available as a speakers’ bureau.
- The council has developed a list of medical associations, education associations, and medical schools throughout Illinois that can be targeted to receive general information on the diagnosis and treatments of PANDAS/PANS.
- The council has exhibited locally at the Illinois Chapter of the American Academy of Pediatrics conferences.

RECOMMENDATIONS FOR THE FUTURE

In keeping with the original goals of P.A. 99-0320, while also expanding upon the council’s goals for 2021, the PANDAS/PANS Advisory Council makes the following recommendations:

Enact Standard Practice Guidelines

Because the National Institute of Mental Health of the National Institutes of Health, the PANDAS/PANS Collaborative Consortium, and the PANDAS Physicians Network have established diagnostic and treatment guidelines that have been published and are now employed by numerous experts and

relevant practicing physicians throughout the country, the council recommends the standardization of care reported here. The council recognizes medicine is an ever changing and evolving field and, as such, also recommends the members of this council stay up-to-date on any new science, research, and protocols to advise as needed.

Develop Mechanisms to Increase Public Awareness

- With IDPH, Illinois Department of Human Services, and other pertinent government agencies, assist in the creation of awareness campaign materials appropriate for doctors' offices and public health clinics.
- Request assistance from the Illinois State Medical Society, the Illinois American Academy of Pediatrics, and other professional societies to disseminate educational materials.
- Encourage appropriate state agencies to provide an educational tab about PANDAS/PANS on their respective websites, or link to the IDPH tab, as well as local resources (treating physicians, support organizations).
- With local group PANDAS/PANS Advocacy and Support of Illinois and assistance from the PANDAS/PANS Clinical Research Consortium, participate in the development of CEU/CME online training for pediatricians, mental health providers, and first responders/emergency departments.
- Investigate the possibility of bringing a PANDAS/PANS Center of Excellence to an Illinois teaching hospital to facilitate prompt recognition and treatment of PANDAS/PANS to ease the burden on the state.
- Increase PANDAS/PANS educational opportunities in 2021. Consider more than one remote learning opportunity to expand understanding. Meetings will pull together individuals from the various specialty areas involved with children and families impacted by PANDAS/PANS and will continue to develop solutions for them. Education on the published treatment guidelines, new science, and the development of treatment resources should address the ongoing challenges of educating health care providers, educational professionals, and families about PANDAS/PANS.
- Develop a flowchart, with the assistance of the Illinois Department of Insurance and the Illinois Department of Labor, for families and doctors to navigate the insurance process more easily.
- Invite a member of the Illinois Chapter of the American Academy of Pediatrics and a member of the Illinois State Medical Society to attend council meetings.
- Investigate the inclusion of coverage of PANDAS/PANS treatment in Medicaid managed care plans.

Provide Outreach to Educators and Parents

- With IDPH, Illinois Department of Human Services, Illinois State Board of Education, and other pertinent government agencies, assist in the creation of awareness campaign materials appropriate for school nurses, school social workers, school psychologists, and school administrators.
- Continue to encourage the use of strep notices and written explanations of school policies regarding the reporting of classroom illnesses and healthy practices to avoid the spreading of disease. Consider basic information on PANDAS/PANS to be added to parent handbooks.
- Increase understanding of available support organizations for families through participation in state agencies' special events, such as the IDPH's School Health Days.
- Provide professional development for teachers and administrators.
- Encourage the utilization of the Illinois Department of Insurance to regulate insurance companies and to protect consumers through assistance and the provision of information about the insurance process.
- Promote the use of the Illinois Office of the Attorney General's Healthcare Bureau to handle consumer issues on health care accessibility.

Increase Understanding of the Burden on Illinois

- Request IDPH and Illinois Department of Insurance gather data and surveillance of incidence statistics on PANDAS/PANS, and its co-occurring conditions, such as autism spectrum disorder, immune deficiencies, or other autoimmune conditions in children.
- Encourage public health-directed means to prevent and treat PANDAS/PANS.
 - Group A Streptococcus (GAS) infections account for an estimated 500,000 deaths every in the U.S. annually. This bacterial pathogen is responsible for a variety of mild and life-threatening infections and the triggering of chronic autoimmune sequelae.⁶¹ A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments.⁶² Prior to the COVID-19 pandemic, researchers worldwide were prioritizing the development of a cost-effective group A Streptococcus vaccine that reduces pharyngitis and tonsillitis.^{61, 62} With marked advances in vaccine technology and coordinated global sharing of information and efforts, a GAS vaccine might evolve more quickly than previously imagined. With world-class academic, industry, and pharmaceutical institutions in Illinois, GAS vaccine research could be incentivized in the post-COVID-19 era.
 - GAS infections are currently tracked by IDPH. Along with IDPH and Illinois public schools, a coordinated public health and school-based initiative to encourage identification and full-course antibiotic treatment for GAS, including information on potential complications of inadequately treated GAS infections, and information on PANDAS/PANS, would be impactful from a primary and secondary public health standpoint.

The PANDAS/PANS Advisory Council will continue to work on its commission to review recommendations concerning standard practice guidelines for PANDAS/PANS, to develop mechanisms to increase clinical awareness of PANDAS/PANS, to provide outreach to educators and parents, and to develop a state network of volunteer experts who can serve as resources.

Advisory council meetings in 2021 will be held bi-monthly via WebEx on the third Tuesday of the relevant month at 9 a.m. Call-in numbers are also available. Tentative dates are January 19, March 16, May 18, July 20, September 21, and November 16, 2021. For more information, or if there is interest in joining the council, contact Allison Nickrent at Allison.Nickrent@Illinois.gov.

PANDAS/PANS has long been a misunderstood condition. However, when it is estimated to effect approximately 1 in 200 children, its potential detriment cannot be ignored. The present available scientific evidence provides an excellent framework for the state of Illinois to impact the positive outcomes for these children and to reduce the potential long-term physical and mental health consequences they may suffer.

CITATIONS

1. Pediatric Developmental Neuroscience: Information About PANDAS. www.nimh.nih.gov. National Institute of Health. Retrieved from <https://www.nimh.nih.gov/labs-at-nimh/research-areas/clinics-and-labs/pdnb/web.shtml>. 2016.
2. Swedo S, Leckman J, and Rose, N: From research subgroup to clinical syndrome: Modifying the PANDAS criteria to describe PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome). *Pediatrics and Therapeutics* 2, 2012. do: 10. 4172/2161-0665.1000113.
3. Swedo S. (2016). Pediatric Acute Onset Neuropsychiatric Syndrome/Autism [presentation slides]. Retrieved from <http://aricinference.com/?p=1904>.
4. Cox CJ, Zuccolo AJ, Edwards EV, Mascaro-Blanco A, Alvarez K, Stoner J, Chang K, and Cunningham MW. Antineuronal Antibodies in a Heterogeneous Group of Youth and Young Adults with Tics and Obsessive-Compulsive Disorder. February 2015, Vol. 25, No. 1: 76-85. *Journal of Child and Adolescent Psychopharmacology*.
5. Cox CJ, Sharma M, Leckman JF, Zuccolo J, Zuccolo A, Kovoov A, Swedo SE, Cunningham MW. Brain Human Monoclonal Autoantibody from Sydenham Chorea Targets Dopaminergic Neurons in Transgenic Mice and Signals Dopamine D2 Receptor: Implications in Human Disease. *J Immunol*. 2013 Dec 1; 191(11): 10.4049. Cox CJ, Sharma M, Leckman JF, Zuccolo J, Zuccolo A, Kovoov A, Swedo SE, Cunningham MW. Brain Human Monoclonal Autoantibody from Sydenham Chorea Targets Dopaminergic Neurons in Transgenic Mice and Signals Dopamine D2 Receptor: Implications in Human Disease. *J Immunol*. 2013 Dec 1; 191(11): 10.4049.
6. Singer HS, Mascaro-Blanco A, Alvarez, K, Morris-Berry C, Kawikova I, Ben-Pazi H, Thompson CB, Ali SF, Kaplan EL, and Cunningham, MW. Neuronal Antibody Biomarkers for Sydenham’s Chorea Identify a New Group of Children with Chronic Recurrent Episodic Acute Exacerbations of Tic and Obsessive Compulsive Symptoms Following a Streptococcal Infection. *PLoS One*. March 20, 2015; 10(3): e0120499.
7. Ben-Pazi H, Stoner JA, Cunningham MW. Dopamine Receptor Autoantibodies Correlate with Symptoms in Sydenham’s Chorea. *PLoS One*. September 20, 2013; 8(9).
8. Yaddanapudi K, Hornig M, Serge R, De Miranda J, Baghban A, Villar G, Lipkin WI. Passive transfer of streptococcus-induced antibodies reproduces behavioral disturbances in a mouse model of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. *Mol Psychiatry*. 2010 Jul; 15(7):712-26.
9. Dileepan, T, Smith, ED, Knowland, D, Hsu, M, Platt, M, Bittner-Eddy, P, Cohen, B, Southern, P, Latimer, E, Harley, E, Agalliu, D, and Cleary, P. Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th-17 cells. *J Clin Invest*. 2016 Jan 4; 126(1):303-17.
10. Murphy, TK, Parker-Athill EC, et al. Cefdinir for recent-onset pediatric neuropsychiatric disorders: a pilot randomized trial. *J Child Adolesc Psychopharmacol*. 2015 Feb; 25(1):57-64.
11. Dale RC, Merheb V, Pillai S, et al., Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. *Brain: a journal of neurology*. Nov 2012; 135(Pt 11):3453-3468.
12. Prof Francesc Graus, Maarten J Titulaer, MD, Ramani Balu, MD, Susanne Benseler, MD, Prof Christian G Bien, MD, Tania Cellucci, MD, Irene Cortese, MD, Prof Russell C Dale, MD, Jeffrey M Gelfand, MD, Michael Geschwind, MD, Carol A Glaser, MD, Prof Jerome Honnorat, MD, Romana Höftberger, MD, Takahiro Iizuka, MD, Sarosh R Irani, MD, Eric Lancaster, MD, Frank Leypoldt, MD, Harald Prüss, MD, Alexander Rae-Grant, MD, Prof Markus Reindl, PhD, Prof Myrna R Rosenfeld, MD, Kevin Rostásy, MD, Albert Saiz, MD, Arun Venkatesan, MD, Prof Angela Vincent, FRS, Prof Klaus-Peter Wandinger, MD, Patrick Waters, PhD, Prof Josep Dalmau. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology*. Volume 15, No. 4, p391–404, April 2016.
13. Williams, KA, Swedo, SE. Post-infectious autoimmune disorders: Sydenham’s chorea, PANDAS and

- beyond. *Brain Res.* 2015 Aug 18; 1617:144-54. Epub 2014 Oct 7 doi: 10.1016/j.brainres.2014.09.071.
14. Murphy, T.K., Snider, L.A., et al., Relationship of movements and behaviors to Group A *Streptococcus* infections in elementary school children. *Biol Psychiatry.* 2007 Feb 1;61(3):279-84.
 15. Swedo SE, et al., Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. *Am J Psychiatry,* 1998.155(2): p. 264-71.
 16. Swedo, SE, Seidlitz J, Kovacevic, M, et. al., Clinical presentation of pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections in research and community settings. *J Child Adolesc Psychopharmacol* 2015 Feb;25(1):26-30
 17. Swedo, SE, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. *Am J Psychiatry,* 1989. 146(2): p246-9.
 18. Garvey, MA, Giedd, J, Swedo, SE. PANDAS: The search for environmental triggers of pediatric neuropsychiatric disorders: lessons from rheumatic fever. *J Childr Neurol* 13(9):413-423, 1998.
 19. Snider, LA, Seligman, LD, et al. Tic and problem behaviors in schoolchildren: prevalence, characterization, and associations. *Pediatrics* 110(2 Pt1):331-6, 2002.
 20. Murphy, ML, Pichichero ME. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). *Arch Pediatr Adolesc Med.* 2002 Apr;156(4):356-61.
 21. Snider, LA, Lougee, L, et al. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. *Biol Psychiatry* 57(7):788-92, 2005.
 22. Garvey, MA, Perlmutter, SJ, et al. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. *Biol Psychiatry.* 45:1465-1571, 1999.
 23. Kirvan, CA, Swedo, SE, Heuser, JS, Cunningham, MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. *Nat Med* 9(7):914-20, 2003.
 24. Kirvan, CA, Swedo, Snider, LA, Cunningham, MW. Antibody-mediated neuronal cell signaling in behavior and movement disorders. *J Neuroimmunol* 2006;179(1-2):173-9.
 25. Perlmutter, SJ, Leitman SF, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. *The Lancet,* 354:1153-1158, 1999.
 26. Kovacevic, M, Grant, P, Swedo, SE. Use of intravenous immunoglobulin in the treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. *J Child Adolesc Psychopharmacol.* 2015 Feb;25(1):65-9.
 27. Latimer ME, L'Etoile N, Swedo SE. Therapeutic plasma apheresis as a treatment for 35 severely ill children and adults with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. *J Child Adolesc Psychopharmacol.* 2015 Feb;25(1):70-5.
 28. Brimberg, L, et al. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. *Neuropsychopharmacology,* 2012. 37(9):2076-87.
 29. Lotan, D, et al. Behavioral and neural effects of intra-stratal infusion of anti-streptococcal antibodies in rats. *Brain Behav Immun,* 2014.
 30. Yaddanapudi, K1, Hornig, M, Serge, R, DeMiranda, J, Baghban, A, Villar, G, Lipkin WI. Passive transfer of streptococcus-induced antibodies reproduces behavioral disturbances in a mouse model of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. *Mol Psychiatry.* 2010 Jul;15(7):712-26. doi: 10.1038/mp.2009.77. Epub 2009 Aug 11.
 31. Chang, K., et al. Clinical Evaluation of Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference.
 32. Swedo, SE., Frankovich, J, and Murphy, TK. Overview of Treatment of Pediatric Acute-Onset Neuropsychiatric Syndrome. *Journal of Child and Adolescent Psychopharmacology.* Volume: 27 Issue 7, September 2017, 27(7): 562-565.
 33. Kovacevic, M. PANDAS/PANS: Current Diagnostic Guidelines in Practice. *PANDAS/PANS: An Update*

- on Current Management and New Treatment Strategies. Georgetown University Hotel and Conference Center, Washington, D.C. 15-16 October, 2016. Lecture.
34. Swedo, SE. PANDAS/PANS: An Update on Current Management and New Treatment Strategies. Georgetown University Hotel and Conference Center, Washington, D.C. October 15-16, 2016. Lecture.
 35. PANDAS Physicians Network. Available at <https://www.pandasppn.org/flowchart/>
 36. "2021 ICD-10-CM Diagnosis Code D89.89." *ICD10Data.Com*, accessed 10 Dec. 2020, <http://www.icd10data.com/ICD10CM/Codes/D50-D89/D80-D89/D89-/D89.89>.
 37. "8E4A.0 Paraneoplastic or Autoimmune Disorders of the Central Nervous System, Brain or Spinal Cord." *ICD-11 for Mortality and Morbidity Statistics*, World Health Organization, accessed 10 Dec. 2020, <https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/496011112>.
 38. Kovacevic, M. PANDAS/PANS: Current Diagnostic Guidelines in Practice. CGH Medical Center, Sterling, IL. 30 Nov. 2016. Grand Rounds Lecture.
 39. PANDAS Network. Understanding-pandas/pans/statistics/. Retrieved from <http://www.pandasnetwork.org>. 2016.
 40. State of Illinois Department of Human Services: Illinois Mental Health 2013-2018 Strategic Plan. Retrieved from <http://www.dhs.state.il.us/OneNetLibrary/27897/documents/Mental%20Health/marysmith/StrategicPlan/MentalHealthServicesFiveYearStrategicPlan2013.pdf>.
 41. National Research Council and Institute of Medicine. Preventing mental, emotional, and behavioral disorders among young people: progress and possibilities. Washington, DC: The National Academic Press; 2009.
 42. Centers for Disease Control and Prevention. Mental health surveillance among children – United States, 2005–2011. *MMWR* 2013;62(Suppl; May 16, 2013):1-35.
 43. Calaprice, D., et al. A Survey of Pediatric Acute-Onset Neuropsychiatric Syndrome Characteristics and Course. *Journal of Child and Adolescent Psychopharmacology*. Volume XX, Number XX, 2017.
 44. Seabury, Seth. "Measuring the Lifetime Costs of Serious Mental Illness and The Mitigating Effects Of Educational Attainment." *Health Affairs*, vol. 38, no. 4, Apr. 2019. *Physicians, Medicare and More*.
 45. Heun-Johnson, Hanke; Menchine, Michael; Goldman, Dana; Seabury, Seth. THE COST OF MENTAL ILLNESS: ILLINOIS FACTS AND FIGURES. March 2019. <https://healthpolicy.usc.edu/wp-content/uploads/2019/05/IL-Chartbook-v3-2019.pdf>. Power Point presentation.
 46. Happold, Madeline. "The Cost of Care." *FourteenEast*, 25 May 2018, <http://fourteeneastmag.com/index.php/2018/05/25/the-cost-of-care/>.
 47. Bardach NS, et al. Common and Costly Hospitalizations for Pediatric Mental Health Disorders. *Pediatrics*. 2014 Apr; 133(4): 602–609.
 48. "Obsessive Compulsive Disorder (OCD) in Children: Boston Children's Hospital." *Boston Children's Hospital*, <http://www.childrenshospital.org/conditions-and-treatments/conditions/o/obsessive-compulsive-disorder-ocd>.
 49. Scahill, Lawrence et al. "The Prevalence of Tic Disorders and Clinical Characteristics in Children." *Journal of obsessive-compulsive and related disorders* vol. 3,4 (2014): 394-400. doi:10.1016/j.jocrd.2014.06.002
 50. Butler M, et al. Neuropsychiatric complications of covid-19 *BMJ* 2020; 371 :m3871
 51. Zhou SJ, Zhang LG, Wang LL, et al. Prevalence and socio-demographic correlates of psychological health problems in Chinese adolescents during the outbreak of COVID-19. *Eur Child Adolesc Psychiatry*. 2020 Jun;29(6):749-758.
 52. Orgilés M, Morales A, Delvecchio E, et al. Immediate psychological effects of the COVID-19 quarantine in youth from Italy and Spain. *PsyArXiv*. <https://psyarxiv.com/5bpfz/>

53. Jaspers-Fayer F, et al. Prevalence of Acute-Onset Subtypes in Pediatric Obsessive-Compulsive Disorder. *J Child Adolesc Psychopharmacol* 2017 May;27(4):332-341.
54. Chena T. Neurological involvement associated with COVID-19 infection in children. *J Neurol Sci.* 2020 Nov 15; 418: 117096. Published online 2020 Aug 13. doi: 10.1016/j.jns.2020.117096
55. Peiris M and Leung GM. What can we expect from first-generation COVID-19 vaccines? *Lancet.* 2020 7-13 November; 396(10261): 1467–1469. Published online 2020 Sep 21.
56. Ludvigsson, JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* 2020 Jun;109(6):1088-1095. Epub 2020 Apr 14.
57. Tsabouri S, et al. Risk Factors for Severity in Children with Coronavirus Disease 2019 A Comprehensive Literature Review. *Pediatr Clin North Am.* 2021 Feb; 68(1): 321–338. Published online 2020 Jul 30.
58. Calaprice D, Tona J, Parker-Athill EC, Murphy TK. A Survey of Pediatric Acute-Onset Neuropsychiatric Syndrome Characteristics and Course. *J Child Adolesc Psychopharmacol.* 2017 Sep;27(7):607-618. doi: 10.1089/cap.2016.0105. Epub 2017 Jan 31. PMID: 28140619.
59. Immune Deficiency Foundation: Immunizations <https://primaryimmune.org/idf-medical-advisory-committee-publishes-vaccination-recommendations/immunizations>
60. Cabanillas B, et al. Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? *Allergy* 2020 Dec 15. doi: 10.1111/all.14711. Online ahead of print.
61. Rivera-Hernandez T, et al. An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model. *mBio* 2019 Apr 30;10(2):e00693-19.
62. Vekemans J, et al. The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics. *Clin Infect Dis.* 2019 Sep 1; 69(5): 877–883.